Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Current Leases (2021 - 2026)

Indivior Pharmaceuticals has reported Current Leases over the past 6 years, most recently at $9.0 million for Q1 2026.

  • For Q1 2026, Current Leases fell 18.18% year-over-year to $9.0 million; the TTM value through Mar 2026 reached $9.0 million, down 18.18%, while the annual FY2025 figure was $10.0 million, 0.0% changed from the prior year.
  • Current Leases for Q1 2026 was $9.0 million at Indivior Pharmaceuticals, down from $10.0 million in the prior quarter.
  • Over five years, Current Leases peaked at $11.0 million in Q1 2025 and troughed at $8.0 million in Q4 2022.
  • A 5-year average of $9.8 million and a median of $10.0 million in 2024 define the central range for Current Leases.
  • Biggest five-year swings in Current Leases: increased 12.5% in 2023 and later decreased 18.18% in 2026.
  • Year by year, Current Leases stood at $8.0 million in 2022, then increased by 12.5% to $9.0 million in 2023, then rose by 11.11% to $10.0 million in 2024, then changed by 0.0% to $10.0 million in 2025, then decreased by 10.0% to $9.0 million in 2026.
  • Business Quant data shows Current Leases for INDV at $9.0 million in Q1 2026, $10.0 million in Q4 2025, and $10.0 million in Q3 2025.